Yu Hayasaka1, Marianna Purgato2, Laura R Magni3, Yusuke Ogawa1, Nozomi Takeshima1, Andrea Cipriani4, Corrado Barbui2, Stefan Leucht5, Toshi A Furukawa1. 1. Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 2. Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Policlinico "G.B.Rossi", Pzz.le L.A. Scuro, 10, Verona 37134, Italy. 3. Psychiatric Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy. 4. Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Policlinico "G.B.Rossi", Pzz.le L.A. Scuro, 10, Verona 37134, Italy; Department of Psychiatry, University of Oxford, Oxford, UK. 5. Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany.
Abstract
BACKGROUND: Dose equivalence of antidepressants is critically important for clinical practice and for research. There are several methods to define and calculate dose equivalence but for antidepressants, only daily defined dose and consensus methods have been applied to date. The purpose of the present study is to examine dose equivalence of antidepressants by a less arbitrary and more systematic method. METHODS: We used data from all randomized, double-blind, flexible-dose trials comparing fluoxetine or paroxetine as standard drugs with any other active antidepressants as monotherapy in the acute phase treatment of unipolar depression. We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d. RESULTS: We included 83 studies (14 131 participants). In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34.0mg/day, agomelatine 53.2mg/day, amitriptyline, 122.3mg/day, bupropion 348.5mg/day, clomipramine 116.1mg/day, desipramine 196.3mg/day, dothiepin 154.8mg/day, doxepin 140.1mg/day, escitalopram 18.0mg/day, fluvoxamine 143.3mg/day, imipramine 137.2mg/day, lofepramine 250.2mg/day, maprotiline 118.0mg/day, mianserin, 101.1mg/day, mirtazapine 50.9mg/day, moclobemide 575.2mg/day, nefazodone 535.2mg/day, nortriptyline 100.9mg/day, reboxetine 11.5mg/day, sertraline 98.5mg/day, trazodone 401.4mg/day, and venlafaxine 149.4mg/day. Sensitivity analyses corroborated the results except for doxepin. LIMITATIONS: The number of studies for some drugs was small. The current method assumes dose response relationship of antidepressants. CONCLUSIONS: Our findings can be useful for clinicians when they switch antidepressants and for researchers when they compare various antidepressants in their research.
BACKGROUND: Dose equivalence of antidepressants is critically important for clinical practice and for research. There are several methods to define and calculate dose equivalence but for antidepressants, only daily defined dose and consensus methods have been applied to date. The purpose of the present study is to examine dose equivalence of antidepressants by a less arbitrary and more systematic method. METHODS: We used data from all randomized, double-blind, flexible-dose trials comparing fluoxetine or paroxetine as standard drugs with any other active antidepressants as monotherapy in the acute phase treatment of unipolar depression. We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d. RESULTS: We included 83 studies (14 131 participants). In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34.0mg/day, agomelatine 53.2mg/day, amitriptyline, 122.3mg/day, bupropion 348.5mg/day, clomipramine 116.1mg/day, desipramine 196.3mg/day, dothiepin 154.8mg/day, doxepin 140.1mg/day, escitalopram 18.0mg/day, fluvoxamine 143.3mg/day, imipramine 137.2mg/day, lofepramine 250.2mg/day, maprotiline 118.0mg/day, mianserin, 101.1mg/day, mirtazapine 50.9mg/day, moclobemide 575.2mg/day, nefazodone 535.2mg/day, nortriptyline 100.9mg/day, reboxetine 11.5mg/day, sertraline 98.5mg/day, trazodone 401.4mg/day, and venlafaxine 149.4mg/day. Sensitivity analyses corroborated the results except for doxepin. LIMITATIONS: The number of studies for some drugs was small. The current method assumes dose response relationship of antidepressants. CONCLUSIONS: Our findings can be useful for clinicians when they switch antidepressants and for researchers when they compare various antidepressants in their research.
Authors: Simon Sanwald; Maximilian Gahr; Katharina Widenhorn-Müller; Carlos Schönfeldt-Lecuona; Kerstin Richter; Bernhard J Connemann; Thomas Kammer; Christian Montag; Markus Kiefer Journal: J Mol Neurosci Date: 2019-11-25 Impact factor: 3.444
Authors: Gretchen Bandoli; Grace M Kuo; Renu Sugathan; Christina D Chambers; Matthieu Rolland; Kristin Palmsten Journal: Arch Womens Ment Health Date: 2018-01-16 Impact factor: 3.633
Authors: Ilana Frydman; Paulo Mattos; Ricardo de Oliveira-Souza; Murat Yücel; Samuel R Chamberlain; Jorge Moll; Leonardo F Fontenelle Journal: Compr Psychiatry Date: 2019-12-16 Impact factor: 3.735